Denis Ravel

5.6k total citations
24 papers, 499 citations indexed

About

Denis Ravel is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Denis Ravel has authored 24 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Physiology, 5 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Denis Ravel's work include Nitric Oxide and Endothelin Effects (3 papers), Pharmacology and Obesity Treatment (3 papers) and Lung Cancer Research Studies (3 papers). Denis Ravel is often cited by papers focused on Nitric Oxide and Endothelin Effects (3 papers), Pharmacology and Obesity Treatment (3 papers) and Lung Cancer Research Studies (3 papers). Denis Ravel collaborates with scholars based in France, United States and Brazil. Denis Ravel's co-authors include Dominique Pépin, Jean Chambaz, G. Béréziat, N Mulliez, Jonathan Kearsey, Catherine de Coupade, Antonio Fittipaldi, Mauro Giacca, Ennio Tasciotti and Françoise Cailler and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes and Biochemical Journal.

In The Last Decade

Denis Ravel

24 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Denis Ravel France 11 248 130 84 68 67 24 499
Donna S. Woodard United States 12 112 0.5× 39 0.3× 26 0.3× 52 0.8× 17 0.3× 14 426
Alena V. Savenka United States 12 148 0.6× 31 0.2× 25 0.3× 21 0.3× 29 0.4× 22 464
Michael A. Hass United States 12 270 1.1× 85 0.7× 27 0.3× 72 1.1× 24 0.4× 16 546
Patricia Madara United States 14 252 1.0× 46 0.4× 14 0.2× 163 2.4× 15 0.2× 19 543
Yuanjie Xie China 13 282 1.1× 23 0.2× 37 0.4× 31 0.5× 103 1.5× 20 839
Emi Nakano Japan 11 77 0.3× 56 0.4× 12 0.1× 48 0.7× 11 0.2× 23 375
Amnon Gonenne United States 8 147 0.6× 33 0.3× 28 0.3× 99 1.5× 42 0.6× 8 425
B. A. John United States 11 113 0.5× 90 0.7× 28 0.3× 62 0.9× 31 0.5× 19 446
Ruth B. Field United States 12 187 0.8× 112 0.9× 12 0.1× 120 1.8× 26 0.4× 21 474
Peter R. Ryle United States 13 108 0.4× 35 0.3× 17 0.2× 62 0.9× 70 1.0× 25 493

Countries citing papers authored by Denis Ravel

Since Specialization
Citations

This map shows the geographic impact of Denis Ravel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Ravel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Ravel more than expected).

Fields of papers citing papers by Denis Ravel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Ravel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Ravel. The network helps show where Denis Ravel may publish in the future.

Co-authorship network of co-authors of Denis Ravel

This figure shows the co-authorship network connecting the top 25 collaborators of Denis Ravel. A scholar is included among the top collaborators of Denis Ravel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Ravel. Denis Ravel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meijer, Laurent, et al.. (2024). Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome. Journal of Alzheimer s Disease. 101(s1). S95–S113. 6 indexed citations
2.
Meijer, Laurent, David Nelson, Vladimir Riazanski, et al.. (2015). 134 Rationale for evaluating (R)-roscovitine (Seliciclib) in patients with cystic fibrosis. Journal of Cystic Fibrosis. 14. S92–S92. 1 indexed citations
3.
Nicolazzi, Céline, Jérôme Quinonero, Vincent Dubois, et al.. (2008). DTS-108, A Novel Peptidic Prodrug of SN38: In vivo Efficacy and Toxicokinetic Studies. Clinical Cancer Research. 14(7). 2145–2153. 58 indexed citations
4.
Ravel, Denis, Vincent Dubois, Jérôme Quinonero, et al.. (2008). Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin. Clinical Cancer Research. 14(4). 1258–1265. 24 indexed citations
5.
Delord, Jean‐Pierre, Patrick Schöffski, Étienne Brain, et al.. (2007). Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2547–2547. 2 indexed citations
6.
Coupade, Catherine de, Antonio Fittipaldi, Ennio Tasciotti, et al.. (2005). Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochemical Journal. 390(2). 407–418. 116 indexed citations
7.
Ravel, Denis, et al.. (2003). ORIGINAL ARTICLE. Differential effects of sulphonylureas on the vasodilatory response evoked by KATP channel openers. Fundamental and Clinical Pharmacology. 17(1). 61–69. 6 indexed citations
8.
Cyrino, F.Z.G.A., Daniel Bottino, Flávio Codeço Coelho, Denis Ravel, & Eliete Bouskela. (2003). Effects of sulfonylureas on KATP channel-dependent vasodilation. Journal of Diabetes and its Complications. 17(2). 6–10. 10 indexed citations
9.
Kohl, Claude, Denis Ravel, Jean Girard, & Jean‐Paul Pégorier. (2002). Effects of Benfluorex on Fatty Acid and Glucose Metabolism in Isolated Rat Hepatocytes. Diabetes. 51(8). 2363–2368. 13 indexed citations
10.
Ravel, Denis, J P Pégorier, R. Jochemsen, et al.. (2000). Beneficial Insulin-Sensitizing and Vascular Effects of S15261 in the Insulin-Resistant JCR:LA-cp Rat. Journal of Pharmacology and Experimental Therapeutics. 295(2). 753–760. 18 indexed citations
11.
Ravel, Denis, et al.. (1998). Acute and Chronic Effects of Dexfenfluramine on the Porcine Pulmonary Artery. General Pharmacology The Vascular System. 30(3). 403–410. 5 indexed citations
12.
Pagano, Patrick J., et al.. (1998). Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits. Diabetologia. 41(1). 9–15. 30 indexed citations
13.
Madani, Tahereh, et al.. (1998). Metabolic and anti-atherogenic effects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus). Life Sciences. 63(1). 65–76. 6 indexed citations
14.
Bailbé, Danielle, et al.. (1998). Effect of gliclazide treatment on insulin secretion and β-cell mass in non-insulin dependent diabetic Goto–Kakisaki rats. European Journal of Pharmacology. 361(2-3). 243–251. 21 indexed citations
15.
Ravel, Denis. (1997). [Benfluorex (Mediator) and non-insulin-dependent diabetes].. PubMed. 335–44. 1 indexed citations
16.
Ravel, Denis & N Laudignon. (1996). Research prospects with benfluorex. Journal of Diabetes and its Complications. 10(5). 246–254. 10 indexed citations
17.
Desta, Barnabas, Daniel Schultz, Denis Ravel, et al.. (1996). Acute and chronic effects of dexfenfluramine on the porcine coronary artery.. Journal of Pharmacology and Experimental Therapeutics. 279(3). 1077–1085. 1 indexed citations
18.
Nanteuil, Guillaume De, Yolande Hervé, J Duhault, et al.. (1995). Euglycaemic and biological activities of novel thiazolidine-2,4-dione derivatives.. PubMed. 45(11). 1176–81. 2 indexed citations
19.
Duhault, J, et al.. (1994). S15261, a new compound for the treatment of the insulin resistance syndrome. Diabetologia. 37(10). 969–975. 11 indexed citations
20.
Ravel, Denis, Jean Chambaz, Dominique Pépin, M. Lisa Manier, & G. Béréziat. (1985). Essential fatty acid interconversion during gestation in the rat. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 833(1). 161–164. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donna S. Woodard Breakdown of academic impact, for papers by Alena V. Savenka Breakdown of academic impact, for papers by Michael A. Hass Breakdown of academic impact, for papers by Patricia Madara Breakdown of academic impact, for papers by Yuanjie Xie Breakdown of academic impact, for papers by Emi Nakano Breakdown of academic impact, for papers by Amnon Gonenne Breakdown of academic impact, for papers by B. A. John Breakdown of academic impact, for papers by Ruth B. Field Breakdown of academic impact, for papers by Peter R. Ryle
Rankless by CCL
2026